Cyclacel Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
BGMS$0.80-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In $000s)
| Three Months Ended · Six Months Ended | ||||
|---|---|---|---|---|
| June 30, | June 30, | |||
| 2025 | 2024 | 2025 | 2024 | |
| Net loss | $(1,318) | $(3,257) | $(1,399) | $(6,203) |
| Translation adjustment | — | (521) | 3,271 | 1,619 |
| Unrealized foreign exchange gain (loss) on intercompany loans | — | 504 | (2,380) | (1,626) |
| Comprehensive loss | $(1,318) | $(3,274) | $(508) | $(6,210) |
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(In $000s, except share amounts)
| Preferred Stock · Common Stock · Additional Paid-in · Other Comprehensive · Accumulated · Total Stockholders’ Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Loss | Deficit | (Deficit) | |
| Balances at December 31, 2023 | 454,537 | $— | 4,412 | $— | $429,797 | $(908) | $(428,282) | $607 |
| Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering | — | — | 915 | — | (80) | — | — | (80) |
| Series B Preferred stock conversions | (119,000) | — | 165 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | 203 | — | — | 203 |
| Unrealized foreign exchange on intercompany loans | — | — | — | — | — | (2,130) | — | (2,130) |
| Translation adjustment | — | — | — | — | — | 2,140 | — | 2,140 |
| Loss for the period | — | — | — | — | — | — | (2,946) | (2,946) |
| Balances at March 31, 2024 | 335,537 | $— | 5,493 | $— | $429,920 | $(898) | $(431,228) | $(2,206) |
| Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses | — | — | 2,029 | — | 6,290 | — | — | 6,290 |
| Stock-based compensation | — | — | — | — | 189 | — | — | 189 |
| Unrealized foreign exchange on intercompany loans | — | — | — | — | — | 504 | — | 504 |
| Translation adjustment | — | — | — | — | — | (521) | — | (521) |
| Loss for the period | — | — | — | — | — | — | (3,257) | (3,257) |
| Balances at June 30, 2024 | 335,537 | $— | 7,522 | $— | $436,399 | $(915) | $(434,485) | $999 |
| Balances at December 31, 2024 | 135,537 | $— | 36,913 | $— | $438,211 | $(891) | $(439,494) | $(2,174) |
| Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses | — | — | — | — | (248) | — | — | (248) |
| Exercise of Pre-Funded Warrants | — | — | 15,277 | — | — | — | — | — |
| Issue of common stock on Securities Purchase Agreement | — | — | 758 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | 1,666 | — | — | 1,666 |
| Issue of Series C preferred stock in Securities Purchase Agreement | 1,000,000 | 1 | — | — | 999 | — | — | 1,000 |
| Series C Preferred stock conversions | (1,000,000) | (1) | 11,042 | — | 1 | — | — | — |
| Issue of Series D preferred stock in Securities Purchase Agreement | 2,100,000 | 2 | — | — | 1,892 | — | — | 1,894 |
| Series D Preferred stock conversions | (1,745,262) | (2) | 799,912 | 1 | 1 | — | — | — |
| Issue of Series E preferred stock in Securities Purchase Agreement | 1,000,000 | 1 | — | — | 999 | — | — | 1,000 |
| Unrealized foreign exchange on intercompany loans | — | — | — | — | — | (2,380) | — | (2,380) |
| Translation adjustment | — | — | — | — | — | 2,385 | — | 2,385 |
| Deconsolidation of foreign operation and transfer of accumulated translation adjustments to net income (loss) | — | — | — | — | — | 886 | (886) | — |
| Loss for the period | — | — | — | — | — | — | (81) | (81) |
| Balances at March 31, 2025 | 1,490,275 | $1 | 863,902 | $1 | $443,521 | $— | $(440,461) | $3,062 |
| Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses | — | — | 940 | — | — | — | — | — |
| Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses | — | — | — | — | 21 | — | — | 21 |
| Issue of Series F preferred stock in Securities Purchase Agreement | 3,000,000 | 3 | — | — | 2,997 | — | — | 3,000 |
| Series D Preferred stock conversions | (354,738) | — | 162,588 | — | — | — | — | — |
| Series E Preferred stock conversions | (1,000,000) | (1) | 458,333 | 1 | — | — | — | — |
| Exercise of Warrants | — | — | 98,202 | — | (1,100) | — | — | (1,100) |
| Stock-based compensation | — | — | — | — | 7 | — | — | 7 |
| Preferred stock dividends | — | — | — | — | (41) | — | — | (41) |
| Loss for the period | — | — | — | — | — | — | (1,318) | (1,318) |
| Balances at June 30, 2025 | 3,135,537 | $3 | 1,583,965 | $2 | $445,405 | $— | $(441,779) | $3,631 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.